Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism
| Autor: | Kadir Demirci, Arif Demirdaş, Ayse Yigit, Kadir Karakuş, Abdülhadi Cihangir Uğuz, Abdullah Akpinar, Ramazan Özcankaya, H. Ramazan Yilmaz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Male
Xanthine Oxidase Physiology Adenosine Deaminase Clinical Biochemistry Nerve Tissue Proteins Pharmacology medicine.disease_cause Nitric Oxide Biochemistry Superoxide dismutase Lipid peroxidation Rats Sprague-Dawley chemistry.chemical_compound Adenosine deaminase Malondialdehyde Paliperidone Palmitate medicine Animals Paliperidone Xanthine oxidase Research Articles chemistry.chemical_classification Brain Chemistry Glutathione Peroxidase Risperidone biology Superoxide Dismutase Glutathione peroxidase Biochemistry (medical) Brain Membrane Proteins Cell Biology Catalase Rats chemistry Purines biology.protein Lipid Peroxidation Oxidation-Reduction Oxidative stress medicine.drug Antipsychotic Agents |
| Popis: | Objective The treatment of schizophrenia is multifactorial, with antipsychotic medications comprising a major part of treatment. Paliperidone is a newly commercialized antipsychotic whose formulation includes the principal active metabolite risperidone, 9-hydroxyrisperidone. Ever since the relationship between schizophrenia and oxidative stress was first demonstrated, many studies have been conducted in order to probe the potential protective effects of antipsychotic drugs on the oxidant–antioxidant system and lipid peroxidation. The basic aim of this study is to determine the effects of the newly marketed drug paliperidone on the activities of the enzymes adenosine deaminase (ADA), xanthine oxidase (XO), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) as well as on malondialdehyde (MDA) and nitric oxide (NO) levels in rat brain tissues. Methods Twenty male Sprague-Dawley rats were used for the study, which were divided into two equal groups. The first was the control group (n = 10) and the second was the paliperidone group (n = 10). Saline was administered once daily for 14 days in the control group. In the paliperidone group, paliperidone was administered once daily with a dose of 1 mg/kg for 14 days. All rats were sacrificed at the end of the fourteenth day. Brain samples were collected and then analyzed. Results Our results demonstrated that paliperidone significantly decreased the activities of ADA (P = 0.015), XO (P = 0.0001), and CAT (P = 0.004) while insignificantly increasing the activity of SOD (P = 0.49), MDA (P = 0.71), and NO (P = 0.26) levels in rat brain tissues. In addition, paliperidone insignificantly decreased the activity of GSH-Px (P = 0.30) compared to the control group in rat brain tissues. Discussion In conclusion, the data obtained in this study suggest that paliperidone can positively alter antioxidant status and, accordingly, can offer positive outcomes in the treatment of schizophrenia by reducing activity in the enzymes ADA and XO, which are associated with purine metabolism. We believe that such a comprehensive approach used with other antipsychotic drugs warrants further study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|